Guardant Health(US:GH)2023-11-06 23:42Shield CRC Screening Test - Shield V2 demonstrated improved clinical sensitivity relative to Shield V1, with CRC sensitivity at 91% (41/45) compared to V1's 84% (38/45) [5, 6, 8] - In Stage I/II CRC, Shield V2 showed 88% (22/25) sensitivity, while V1 had 76% (19/25) sensitivity [10] - Adding Shield to the standard of care increases compliance meaningfully [3] - Patients were more than 2x more likely to complete CRC screening when offered a blood-based test like Shield [37] - The company is blazing a trail to the first FDA approved and reimbursed CRC screening test [21] Financial Performance and Growth - Total revenue reached $143 million, with precision oncology revenue at $133.4 million, a 31% year-over-year growth [35, 50] - Clinical volumes increased to 43900 [45] - Biopharma volumes grew by 11% year-over-year [25] - The company is raising its guidance for FY 2023 revenue to $553 - $556 million, representing 23-24% year-over-year growth [63] Therapy Selection and MRD - Guardant360 ASP is trending to $2700 due to recent commercial coverage [18] - Interim data from the PEGASUS study suggests Reveal can be used to help modulate therapy for CRC patients, with 34% of patients with a positive liquid biopsy result after surgery experiencing cancer relapse despite adjuvant chemotherapy, compared to only 10% of patients with a negative result [19]